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Patently Unfair Trade 
India's state-protected pharmaceuticals industry is being 
patented, privatised and plundered by WTO trade rules, 
argues HANS LOFGREN 
India's pharmaceutical industry, the world's fourth largest by volume, is a major exporter of relatively cheap generic medicines to both developed and developing countries. In 
2001, the Mumbaj-based firm Cipla commenced exports of a 
generic version of a triple-combination drug for the treat-
ment of HIV / AIDS to Africa for around US$350 (for a one-
year course). The price chflrged by the multinational drug 
companies was around US$12,QOO. The response of the 'big 
pharma' companies, supported by the US government, was 
to attack the Indian firms and their customers, notably 
the South African government, in the courts and the interna-
tional institutions. This caused public outrage that ultimately 
forced a withdrawal of the legal action against South Africa, 
and the prices for HIV / AIDS drugs charged by the multina-
tionals were also lowered. Still, the need for HIV / AIDS 
drugs in developing countries is far from being met, 
and US resistance to generics remains a key factor 
hampering supply. 
encourage the development of nn indigenous pharmaceutical 
industry and to provide access to low-cost medicines. All in 
all, until recently, India was an unattractive market for the 
multinationals and many abandoned the country altogether. 
In 1970, domestic companies supplied only around 20 per 
cent of the drug market; by the 19908 this figure had 
increased to around 80 per cent and India had achieved self-
sufficiency in the production of most basic medicines. But 
the nationalist period of state-protected industry develop-
ment has now come to an end. Since 1991, India has 
embarked on a shift towards liberalisation, pl'ivatisation, and 
integration into global markets, and the pharmaceutical sec-
tor has been progressively 'opened up' in respect of trade 
and foreign investment. TI1e election in 2004 of the Congress-
led United Progressive Alliance (UPA) government, 
supported in parliament by the Communist Party of India 
(Marxist) and other Left pflrties, is unlikely to change the 
general direction of economic policy. 
Recently, the Indian govern-
ment re-introduced product 
patents for pharmaceuticals, 
India's period of state-protected industry 
development has now come to an end. 
which will impede access to 
affordable drugs - including 
new HJV / AIDS medications -
for tl1e poor in India and other 
developing countries. The new 
patent regime has been forced on 
India by the World Trade 
Organisation (WTO) and the 
The pharmaceutical sector has been progressively 
'opened up' to trade and foreign investment. 
Large-scale Indian exports of generic medicines were made 
possible by the absence of product patents for drugs, which 
were abolished (along with patents for agro-chemical prod-
ucts) in the early 19705. Process patents were recognised hut 
firms were free to develop alternative processes to manufac-
ture a wide range of bulk and finished drugs at low cost. 
There were also high tariffs and restrictions on the importa-
tion of re~dy·made fonnullltions, and transnational drug 
companies were required to reduce their stake in their 
Indiiln subsidiaries. The Indira Gandhi Government of that 
period subscribed (in some respects at least) to Nehru's 
vision of autonomous industrialisation, and sought to 
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requirements of the TRIPS agree-
ment (Trade Related aspects of 
Intellectual Property Rights). 
TRIPS is one of the three pillars of the WTO along with trade 
in goods and services. The now taken-far-granted linkage 
between international trade regulation and intellectual 
property rights (IPR) is the outcome of an initially covert 
lobbying campaign by the transnational pharmaceutical 
companies from the 19805, which received early endorse-
ment by the US government. This campaign was remarkably 
successful, and when the WTO was established in 1995 a 
global IPR system was adopted as a central aim. At the time, 
IPRs (patents, copyright, trademarks, for example) attracted 
little public debate and scrutiny, but since the eruption of the 
'anti-gJobalisation' movement at the WTO Seattle meeting in 
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1999 their social and economic implications have been paid 
ever-increasing attention by social movements and critical 
analysts. In recent years, the debate has also been fuelled by 
the increasingly aggressive pursuit of strong rPRs by the 
pharmaceutical, software, publishing, entertainment and 
other industries. in India, a fierce political battle is now 
being waged over drug patents that has far-reaching impli-
cations for other developing cOtU1tries that have come to rely 
on access to relatively affordable Indian generic drugs. 
TRIPS requires twenty-year product patents in all fields, 
including medicines, and obliges signatory states to provide 
effective enforcement. mechanisms. Developing countries 
were given a transition period until 2005 and the least devel-
oped countries until 2016. Before WTO, nations could design 
IPR legislation in accordance with their particular circum-
stances and in many countries pharmaceutical patents were 
not recognised. Indeed, most OECD countries introduced 
philrmaceutical patents only when they had reached a high 
stage of economic development. Thus Japan introduced drug 
patents in 1976, Switzerland in 1977, Holland, Hilly and 
Sweden in 1978, tinct Spain and Norway in 1992. Yet devel-
oping countries, with huge public health needs and virtually 
no drug patents to protect, are now prevented by TRIPS and 
US intimidation from adopting IPR arrangements consistent 
with their economic and social circumstances. 
TRIPS recognises some 
new UPA government was and remains in a quandary in 
respect of product patents and TRIPS, not least as a conse-
quence of its parliamentary reliance on the Left parties. On 
26 December 2004, as the WTO deadline of 1 January 2005 
was about to expire, a revised version of the former govern-
ment's patents bill was introduced as a Presidential ordi-
nance. This decree is now the subject of intense debate. 
Of particular concern to many domestic drug firms, social 
movements and the Left is the point also made by an 
editorial in the New York Times (18 January 2005): 
The decree is so tilted toward the pharmaceutical il1dustry thllt it 
does /lot eVe/l lake advlllltage of rights coulltries enjoy !lIuler the 
WTO to protect public hea/tlr. 
The precise implications of the new IPR regulations are not 
yet clear, and amendments are likely when the bill is pre-
sented to parliament, but the critical change is that the 
'reverse engineering' model, which underpinned the expan-
sion of India's pharmaceutical industry in the past three 
decades, is now disallowed. New drugs will be granted 
patents for twenty years (previously process patents only 
applied for five to seven years). Prices for new medicines 
will be substantially higher than would have been the case 
under previous arrangements. Patents will also be granted 
for some drugs already on the market (thousands of applica-
tions are pending) which will result in generic versions 
public health safeguards and 
these were re-affirmed, at the 
instigation of India and other 
developing cOlmtries, in the 
Doha Declaration of 2001, 
which states that 'the TRIPS 
. agreement does not and 
should not prevent members 
from taking measures to pro-
tect public health' and, 'the 
agreement can and should be 
interpreted and implemented 
in a manner supportive of 
WTO members' right to pro-
India now beckons as a profitable market with a huge 
potential for expansion. An executive of a 
pharmaceutical company was recently quoted as 
saying: There could easily be 70 to 80 million people 
[in India] who can afford expensive medicines, 
just as they go out and buy expensive cars, 
branded clothes and consumer goods. 
tect public health und, in 
particular, to promote access to medicines for all'. 
But the practical significance of such pronouncements is 
undermined by pressures from the multinational drug com-
panies, the US government, and also the European Union, 
whose objective is the implementation - through regional 
and bilateral trade agreements (such as the one recently 
entered into with Australia) and general bullying - of 
'TRIPS plus' provisions that go beyond the requirements of 
the WTO. Most developing countries lack both the technical 
resources to negotiate effectively in the very complex area of 
IPRs and the political and economic power to stand up to 
global companies ilnd the governments in the US and 
Europe. A further threilt to flexibilities notionally available 
under TRIPS is emerging from within the World Intellectual 
Property Organization (WIPO), where the US and its allies 
are pursuing the aim of"a fully harmonised globallPR 
system that would do away with any leeway for 
nntionallegislators. 
The Indian Patents Act has been modified in the past 
decade to bring it closer to TRIPS, but the government pro-
crastinated on the most crucial step - the intmduction of 
product patents - due to strong opposition by sections of 
the domestic pharmaceutical industry and public health 
groups. By late 2003, the Bharatiya Janata PMty (BJP) gov-
ermnont had pt'Cp"red a final amendment bill but its elec-
toral defeat put a stop to its passage through parliament. The 
having to be withdrawn, driving up the cost of these medi-
cines in India and in countries to which India exports. For 
example, it will not be possible to produce and export gener-
ic versions of post-1995 or any future 'second line' 
HIV / AIDS medicines - prescribed when the effectiveness 
of 'first-line' cheaper medications has been exhausted -
unless voltmtarily licensed by the patent holdel: The new 
legislation also includes 'data exclusivity' provisions that are 
likely to further impede the timely introduction of generics. 
The term 'data exclusivity' refers to the prevention of <1ccess 
for generic companies to clinical trial and other data lodged 
with national regulators by the originator (multinational) 
company. This can be a means (distinct from patents) of 
extending the mnrketing monopoly enjoyed by originator 
companies, and 'data exclusivity' is pursued aggressively 
through many of the recent so-called free trade <1greements 
(including an agreement with a group of Central 
American countries). 
For the multinationnl drug companies, India now beckons 
as a profitable market with a huge potential for expansion. 
An executive was recently quoted as saying: 
Tilere collid ca,i!y be 70 to 80 millioll people (ill [Jldirl] who CllII 
a]Jord expellsive IIIcdicill<:o, just as tlrey go Ollt I1lld buy expellsive 
CMS, b/'tl/1ded clot/II'S aJ1d conSUl/WI' goods. That is equlll to tire size 
afn UK or a Gel'llrrlllY (Reuters, quoted on IP health 30 
December 2004 <lists.essential.org/pipennail/ip-
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health /2004-December /007323.html». 
This is a vision Ihilt excludes the health and wellbeing of 
hundreds of millions of Indians living in poverty. 
Proponents of the TRIPS regime argue that the impact on 
consumers will be marginal since most drugs are out of 
patent and will continue to be a\'ailable as generics. Their 
view is also that IPRs provide incentives for research and 
development to discover new medicines, and the future of 
the Indian industry is said to be in discovery and imlOvation 
rather than 'reverse engineering'. Further, it is suggested that 
India now' has a bright future as a location for investments in 
drug production and research. 
But, as already noted, existing drugs eligible for patent 
protection and all drugs introduced in the future will be 
priced in India at a level beyond the reach of most of the 
pop1.1Iation. There is also the distinct possibility that the 'big 
pharma' companies will reverse to the pre-1970s practice of 
supplying the Indian drug market largely through imports. 
The most advanced of the domestic firms will be further 
integrated into the global innovation and production net-
works of the multinationals, defusing the competitive threat 
posed by hitherto relatively independent, highly efficient 
Indian generics manufacturers. Nor will the introduction of 
product patents bring about, in the foreseeable future, 
research and development activities of significant magni-
tude. Although more research and development is 
undertaken than a decade ago and there are reports of inter-
est in locating more clinical trials to India, these are marginal 
activities in the context of the Indian pharmaceutical sector 
as a whole or global research and development in the bio-
sciences. The research and development wldertaken by the 
multinationals is directed, first and foremost, at the cllronic 
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disellSCs of the rich, and Indian firms oriented towards the 
world market operate according to the same logic. The 
Indian government's Pl1llu1ing Commission posits that 'pri-
ority needs to be given for the initiation ot new drug devel-
opment for diseases of relevance to the Indifm population', 
but needs-driven discovery research or, for that miltler, the 
supply of cs~ential drugs as public goods, is not easily recon-
ciled with success in a globally integrated pharmaceutical 
market. It is striking that HIV / AIDS medications are not 
widely available to Indian patients despite the ground-
breaking role of Indian companies in exporting relatively 
cheap generic HIV / AIDS drugs. 
In response to these changes, public health activists in India 
are currently building a domestic and global campaign 
under the slogan 'Right to Health' for modifications to the 
proposed patent legislation, co-ordinated through the Global 
Campaign against Indian Patents Amendment (GCAIPA 
<www.gcaipa.org». 
This campaign faces an uphill battle. The forces that are 
now reshaping the Indial1 pharmaceutical industry will not 
bring about an improvement in the health conditions of the 
vast majority of the population. The significance of the new 
patent regime is that India is again an open market with 
drug regulation compliant with the needs the multinational 
companies. Soon it will be possible to look back at the period 
of state support for an autonomous domestic industry as an 
historical interlude. 
HailS Lofgrm teaches Politics aHd Public Policy at 
Deakin University. He recel1tly visited India to study 
developments il1 tile drug illdustry. 
